Oxford Scientists Reveal Sunlight-Powered Anti-Cancer Breakthrough
OXFORD, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Dr. Daniel Chen,…
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc.…
RevitaLash Cosmetics Announces Road to $10 Million Goal in Support of Breast Cancer Initiatives
VENTURA, Calif., April 15, 2025 /PRNewswire/ -- RevitaLash® Cosmetics, globally recognized for…
Ezra Appoints Dr. Danna Chung as Chief Medical Officer
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Ezra, the healthcare AI…
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
April 10, 2025 16:05 ET | Source: Protara Therapeutics NEW YORK, April…
Arkade Developers Supports 263 Cancer Patients Through Care Per Sq Ft Initiative, Collects 122 Blood Units in Strong Partnership with Tata Memorial Hospital and Sajjan Jain Trust
MUMBAI, India, April 7, 2025 /PRNewswire/ -- Arkade Developers Limited, through its…
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 04, 2025 16:05 ET | Source: Syndax Pharmaceuticals, Inc. NEW YORK,…
NCCN 2025 Annual Conference Illustrates the Critical Impact of Cancer Research on Improving Lives
The National Comprehensive Cancer Network celebrated its 30th anniversary with a series…
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit…
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples…